Is aspirin useful in primary prevention?

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Background:

• Aspirin is widely believed to prevent cardiovascular events by inhibiting thrombus formation.
• However, alternative mechanisms of plaque instability, such as hemorrhage from vasa vasorum, are not addressed by aspirin.
• Existing evidence on aspirin's benefits is questioned due to potential biases in meta-analyses.

Purpose of the Study:

• To critically evaluate the evidence for aspirin's efficacy in cardiovascular disease prevention.
• To assess the risks associated with long-term aspirin use.
• To examine the reliability of current meta-analyses and clinical trial data regarding aspirin.

Main Methods:

• Review and critical analysis of existing clinical trial data and meta-analyses on aspirin's cardiovascular effects.
• Examination of theoretical mechanisms for aspirin's action versus observed clinical outcomes.
• Assessment of potential biases in meta-analytic studies.

Main Results:

• No convincing evidence supports aspirin for primary cardiovascular event prevention.
• Long-term aspirin use, even in patients with known cardiovascular disease, is not supported by current data.
• Aspirin is associated with serious risks, including gastrointestinal and intracranial bleeding.
• Low-dose aspirin (50-100 mg/day) lacks demonstrated benefit in common clinical settings.
• Potential for aspirin to interfere with beneficial cardiovascular drugs, like ACE inhibitors.
• Evidence for cancer reduction is old and not applicable to current dosing strategies.

Conclusions:

• The purported benefits of aspirin in cardiovascular prevention are not substantiated by reliable evidence.
• The risks of serious bleeding associated with aspirin outweigh any potential benefits in most clinical scenarios.
• Current low-dose aspirin regimens lack proven efficacy for cardiovascular disease prevention or other common clinical indications.